Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This is Phase 2, open label, multi-center study to assess safety and efficacy of vactosertib
in combination with pembrolizumab as 1st line treatment for subjects with advanced or
metastatic, PD-L1 positive, non-small cell lung cancer (NSCLC) who have not previously
received systemic therapy for advanced disease and in whom EGFR, ALK, BRAF, ROS1-directed
therapy is not indicated.